Descriptive only
Discontinuation due to gastrointestinal adverse events
Polycystic ovary syndrome
longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)Separate part 2 of a disconnected network
2
Randomized trials
3
Treatments
118
Participants
4
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 2 trials. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Sex (percent female) effect modifier, prognostic factor; 1 of 2 | Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 2 of 2 |
|---|---|---|
| NCT04876027 S000699 | not reported | 100 region: all sites in Asia |
| NCT04029272 S000952 | 100 | 100 region: all sites in Asia |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Sex: not reported by 1 of 2 trials
- NoteOutcome assessment, time point: selected time points span 12 to 26.07 weeks
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04876027 | 26.07 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | open_label | non_industry | 2021 | women 18 to 45, BMI 24 or higher, PCOS by Rotterdam criteria |
| NCT04029272 | 12 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | open_label | non_industry | 2019 | women 18 to 40 years; Rotterdam PCOS; BMI 25 or more; no diabetes |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT04876027 | A1 | DULA_SC_1p5MG_QW | 26.07 | arm, events | 2 / 35 | R0009547:Results | |||
| NCT04876027 | A2 | STANDARD_CARE | 26.07 | arm, events | 0 / 33 | R0009547:Table 3 | |||
| NCT04029272 | A1 | STANDARD_CARE | 12 | arm, events | 1 / 25 | R0011463:Results | |||
| NCT04029272 | A2 | EXENER_SC_2MG_QW | 12 | arm, events | 1 / 25 | R0011463:Results |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.